medigraphic.com
ISSN 0016-3813 (Impreso)

2009, Número 1

<< Anterior Siguiente >>

Gac Med Mex 2009; 145 (1)


Fundamentos para el tratamiento de la espondilitis anquilosante y su efecto en la reumatología mexicana

Burgos-Vargas R, Abud-Mendoza C, Díaz-Jouanen E, Garza-Elizondo MA, Medrano-Ramírez G, Orozco-Alcalá J, Pacheco-Tena C, Pineda-Villaseñor C, Carlos-Pozos J, Ramos-Niembro F, Robles-San Románk M, Santana-Sahagún E

Idioma: Español
Referencias bibliográficas: 53
Paginas: 41-50
Archivo PDF: 96.91 Kb.


RESUMEN

Esta revisión trata de los fundamentos sobre los que descansa el tratamiento actual de la espondilitis anquilosante, enfatizando la participación y la opinión de la comunidad reumatológica nacional. En la temática se incluye la repercusión de la enfermedad —aspectos epidemiológicos, laborales, económicos, estado de salud y calidad de vida—, propuestas para la identificación de la espondiloartritis axial como la forma más precoz de la espondilitis anquilosante y el análisis de la literatura que dio origen a las recomendaciones terapéuticas actuales. Con relación al último punto, se abordan las recomendaciones ASAS/EULAR para el tratamiento de la espondilitis anquilosante y el nivel de concordancia con la opinión del reumatólogo mexicano y de otros países. Finalmente, se analizan las recomendaciones para iniciar bloqueadores del factor de necrosis tumoral en pacientes con espondilitis anquilosante.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Braun J, Sieper J. Ankylosing spondylitis. Lancet 2007;369:1379-1390.

  2. Akkoc N, Khan MA. Epidemiology of ankylosing spondylitis and related spondyloarthropathies. En: Weisman MH, van der Heijde D, Reveille JD, editors. Ankylosing spondylitis and the spondyloarthropathies. Philadelphia: Mosby Elsevier; 2006. pp. 117-131.

  3. Fraga A, Gorodezky C, Lavalle C, Castro-Escobar LE, Magaña L, Escobar-Gutiérrez A. HLA-B27 in Mexican patients with ankylosing spondylitis. Arthritis Rheum 1979;22:302.

  4. Arellano J, Vallejo M, Jiménez J, Mintz G, Kretschmer RR. HLA-B27 and ankylosing spondylitis in the Mexican mestizo population. Tissue Antigens 1984;23:112-116.

  5. Burgos-Vargas R, Naranjo A, Castillo J, Katona G. Ankylosing spondylitis in the Mexican mestizo: Patterns of disease according to age at onset. J Rheumatol 1989;16:186-191.

  6. Burgos-Vargas R, Granados Arriola J. Ankylosing spondylitis and related diseases in the Mexican mestizo. En: Khan MA, editor. Seronegative spondyloarthropathies. Spine: State of the Art Reviews 4:665-678, Philadelphia:Hanley & Belfus; 1990.

  7. Ramos-Remus C, Macías MA, Suárez-Almazor ME, Prieto RE, Gutiérrez-Ureña S. Labor status and working days losts in a consecutive sample of 103 patients with ankylosing spondylitis. Arthritis Rheum 1997;40(supl):S263.

  8. Morales-Romero J, Villa-Manzano R, Celis A, Gámez-Nava JI, González-López L. Incapacidad e invalidez para el trabajo en espondilitis anquilosante: Parte II, costo estimado en días laborales perdidos. Reumatol Clin 2008;4(supl 1):5-6.

  9. Peláez-Ballestas I, Burgos-Vargas R, Vázquez-Mellado J, Hernández-Garduño A, Bernard A, Garza M, et al. Medición del estado de salud (sf-36) en enfermedades reumáticas: Estudio multicéntrico. Reumatol Clin 2006;2(supl 1):60.

  10. Julián-Santiago F, Peláez-Ballestas I, Hernández-Garduño A, Carvajal-Arroyo LA, Terán L, Garza M, et al. Evaluación de la calidad de vida de pacientes en una cohorte de pacientes con espondilitis anquilosante. Reumatol Clin 2007;3(supl 1):42.

  11. Duarte-Salazar C, Guzmán-Vázquez S, Soto-Molina H, Cháidez-Rosales P, Ilizaliturri-Sánchez V, Nieves-Silva J, et al. Disability impact on quality of life in Mexican adults with juvenile idiopathic arthritis and juvenile ankylosing spondylitis. Clin Exp Rheumatol 2007;25:922-927.

  12. Mould-Quevedo J, Peláez-Ballestas I, Vázquez-Mellado J, Terán-Estrada L, Esquivel-Valerio J, Ventura L; Grupo REUMAIMPACT. El costo de las principales enfermedades reumáticas inflamatorias desde la perspectiva del paciente en México. Gac Med Mex (en prensa).

  13. Darby SC, Doll R, Gill SK, Smith PG. Long term mortality after a single treatment course with X-rays in patients treated for ankylosing spondylitis. Br J Cancer 1987;55:179-190.

  14. Weiss HA, Darby SC, Fearn T, Doll R. Leukemia mortality after X-ray treatment for ankylosing spondylitis. Radioter Res 1995;142:1-11.

  15. Elyan M, Khan MA. The role of nonsteroidal anti-inflammatory medications and exercise in the treatment of ankylosing spondylitis. Curr Rheumatol Rep 2006;8:255-259.

  16. van der Heijde D, Baraf HS, Ramos-Remus C, Calin A, Weaver AL, Schiff M, et al. Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: Results of a 52-week randomized controlled study. Arthritis Rheum 2005; 52:1205-1215.

  17. Gossec L, van der Heijde D, Melian A, Krupa DA, James MK, Cavanaugh PF, et al. Efficacy of cyclo-oxygenase-2 inhibition by etoricoxib and naproxen on the axial manifestations of ankylosing spondylitis in the presence of peripheral arthritis. Ann Rheum Dis 2005;64:1563-1567.

  18. Wanders A, Heijde D, Landewé R, Béhier JM, Calin A, Olivieri I, et al.Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 2005;52:1756-1765.

  19. Chen J. Liu C. Is sulfasalazine effective in ankylosing spondylitis? A systematic review of randomized controlled trials. J Rheum 2006;33:722-731.

  20. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: A randomized controlled multicentre trial. Lancet 2002;359:1187-1193.

  21. Breban M, Vignon E, Claudepierre P, Devauchelle V, Wendling D,Lespessailles E, et al. Efficacy of infliximab in refractory ankylosing spondylitis: Results of a six-month open-label study. Rheumatology 2002;41:1280- 1285.

  22. Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002;346:1349-1356.

  23. Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester G, et al. Long term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: An open, observational, extension study of a three-month, randomized, placebocontrolled trial. Arthritis Rheum 2003;48:2224-2233.

  24. Davis JC Jr, Van der Heijde D, Braun J, Dougados M, Cush J, Clegg DO,et al. Enbrel Ankylosing Spondylitis Study Group. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: A randomized, controlled trial. Arthritis Rheum 2003;48:3230-3236.

  25. Davis J Jr, Webb A, Lund S, Sack K. Results from an open-label extension study of etanercept in ankylosing spondylitis. Arthritis Rheum 2004;51:302- 304.

  26. Kruithof E, Baeten D, van den Bosch F, Mielants H, Veys EM, De Keyser F. Histological evidence that infliximab treatment leads to down regulation of inflammation and tissue remodeling of the synovial membrane in spondyloarthropathy. Ann Rheum Dis 2005;64:529-536.

  27. Van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, et al. Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group. Efficacy and safety of infliximab in patients with ankylosing spondylitis: Results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005;52:582-591.

  28. Baraliakos X, Brandt J, Listing J, Haibel H, Sorensen H, Rudwaleit M, et al. Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: Clinical and magnetic resonance imaging data. Arthritis Rheum 2005;52:856-863.

  29. Davis JC, Van der Heijde DM, Braun J, Dougados M, Cush J, Clegg D, et al. Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks. Ann Rheum Dis 2005;64:1557-1562.

  30. Kruithof E, De Rycke L, Roth J, Mielants H, Van den Bosch F, De Keyser F, et al. Immunomodulatory effects of etanercept on peripheral joint synovitis in the spondylarthropathies. Arthritis Rheum 2005;52:3898-909.

  31. Haibel H, Rudwaleit M, Brandt HC, Grozdanovic Z, Listing J, Kupper H,et al. Adalimumab reduces spinal symptoms in active ankylosing spondylitis: Clinical and magnetic resonance imaging results of a fifty-two-week open-label trial. Arthritis Rheum 2006;54:678-681.

  32. Braun J. Landewe R. Hermann KG. Han J. Yan S. Williamson P, et al.ASSERT Study Group. Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. Arthritis Rheum 2006;54:1646-1652.

  33. van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, et al. ATLAS Study Group. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006;54:2136-2146.

  34. Schett G, Landewé R, van der Heijde D. Tumour necrosis factor blockers and structural remodeling in ankylosing spondylitis: what is reality and what is what is fiction? Ann Rheum Dis 2007;66:709-711.

  35. Baraliakos X, Listing J, Brandt J, Haibel H, Rudwaleit M, Sieper J, et al.Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-alpha antibody infliximab. Rheumatology 2007;46(9):1450-1453.

  36. Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis 2004;63:665-670.

  37. Burgos-Vargas R, Rojas-Serrano J. Predictors of response to tumor necrosis factor-alpha blockers in ankylosing spondylitis. J Rheumatol 2005;32:1637- 1640.

  38. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-368.

  39. Feldtkeller E, Khan MA, van der Heijde D, van der Linden S, Braun J. Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. Rheumatol Int 2003;23:61-66.

  40. Rudwaleit M, van der Heijde D, Khan MA, Braun J, Sieper J. How to diagnose axial spondyloarthritis early. Ann Rheum Dis 2004;63:535-543.

  41. Burgos-Vargas R. Undifferentiated spondyloarthritis: A global perspective.Curr Rheumatol Rep 2007;9:361-366.

  42. Rudwaleit M, Metter A, Listing J, Sieper J, Braun J. Inflammatory back pain in ankylosing spondylitis: A reassessment of the clinical history for application as classification and diagnostic criteria. Arthritis Rheum 2006;54:569-578.

  43. Calin A, Porta J, Fries JF, Schurman DJ. Clinical history as a screening test for ankylosing spondylitis. JAMA 1977;237:2613-2614.

  44. Huerta-Sil G, Casasola-Vargas JC, Londoño JD, Rivas-Ruiz R, Chávez J, Pacheco-Tena C, et al. Low grade radiographic sacroiliitis as prognostic factor in patients with undifferentiated spondyloarthritis fulfilling diagnostic criteria for ankylosing spondylitis throughout follow up. Ann Rheum Dis 2006;65:642-646.

  45. Zochling J, van der Heijde D, Dougados M, Braun J. Current evidence for the management of ankylosing spondylitis: A systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis.Ann Rheum Dis 2006;65:423-432.

  46. Zochling J, van der Heijde D, Burgos-Vargas R, Collantes E, Davis JC Jr,Dijkmans B, et al. ‘ASsessment in AS’ International Working Group; European League Against Rheumatism. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006;65:442-452.

  47. Shekelle PG, Woolf SH, Eccles M, Grimshaw J. Clinical guidelines: Developing guidelines. BMJ 1999;318:593-596.

  48. Simón JA, Burgos-Vargas R. Agreement of Mexican rheumatologists with the ASsessment in Ankylosing Spondylitis International Working Group and the European League Against Rheumatism recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006;65:1535-1536.

  49. Gossec L, Dougados M, Phillips C, Hammoudeh M, de Vlam K, Pavelka K, et al. Dissemination and evaluation of the ASAS/EULAR recommendations for the management of Ankylosing Spondylitis: Results of a study among 1507 rheumatologists. Ann Rheum Dis 2007 Nov 29 [Epub ahead of print]

  50. Comité Mexicano del Consenso de Biológicos. Colegio Mexicano de Reumatología.Guías y recomendaciones del Colegio Mexicano de Reumatología para el uso de agentes biológicos en enfermos reumáticos. Reumatol Clin 2006;2:78-89.

  51. Pham T, Landewé R, van der Linden S, Dougados M, Sieper J, Braun J,et al. An international study on starting tumour necrosis factor-blocking agents in ankylosing spondylitis. Ann Rheum Dis 2006;65:1620-1625.

  52. Braun J, Pham T, Sieper J, Davis J, van der Linden S, Dougados M, et al.ASAS Working Group. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003;62:817-824.

  53. Braun J, Davis J, Dougados M, Sieper J, van der Linden S, van der Heijde D. ASAS Working Group. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 2006;65:316-320.




2020     |     www.medigraphic.com